Literature DB >> 22460228

Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment.

K R Amico1, Vanessa McMahan, Pedro Goicochea, Lorena Vargas, Julia L Marcus, Robert M Grant, Albert Liu.   

Abstract

The recent successes of biomedical HIV prevention approaches have sparked considerable debate over the scalability, feasibility, and acceptability of pre-exposure prophylaxis (PrEP) as a widespread prevention strategy for men who have sex with men and trans-gender. Anticipated difficulties with PrEP adherence and concerns about resources required to best support it have tempered enthusiasm of PrEP demonstration projects and roll-out. While no evidence-based approach for supporting PrEP use is presently available, a number of approaches have been developed in the context of double-blind, randomized, placebo-controlled trials of PrEP that can provide guidance in moving forward with real world support of open label PrEP use. We present the development, implementation and evaluation of feasibility and acceptability of next-step counseling (NSC) and neutral assessment (NA), the adherence support and promotion of accurate reporting approaches used in the late phases of the iPrEx study. Evaluation of the approach from the perspective of implementers of over 15,000 NSC sessions in seven different countries with almost 2,000 iPrEx participants provided support for NSC, its brevity (averaging ~14 min per follow-up session) and overall acceptability and feasibility. NA also was generally well supported, with a majority of study staff believing this approach was feasible and acceptable; however, lower acceptability for certain aspects of NA was noted amongst staff reporting NA was different from their previous interview approach. Quantitative and qualitative data gathered from implementers were used to make modifications for supporting PrEP use in the open-label extension of iPrEx.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22460228     DOI: 10.1007/s10461-012-0182-5

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  47 in total

1.  Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection.

Authors:  K Rivet Amico; Julia L Marcus; Vanessa McMahan; Albert Liu; Kimberly A Koester; Pedro Goicochea; Peter L Anderson; David Glidden; Juan Guanira; Robert Grant
Journal:  J Acquir Immune Defic Syndr       Date:  2014-08-15       Impact factor: 3.731

2.  An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM.

Authors:  Sybil G Hosek; Bret Rudy; Raphael Landovitz; Bill Kapogiannis; George Siberry; Brandy Rutledge; Nancy Liu; Jennifer Brothers; Kathleen Mulligan; Gregory Zimet; Michelle Lally; Kenneth H Mayer; Peter Anderson; Jennifer Kiser; James F Rooney; Craig M Wilson
Journal:  J Acquir Immune Defic Syndr       Date:  2017-01-01       Impact factor: 3.731

3.  Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery.

Authors:  Susanne Doblecki-Lewis; Stephanie Cohen; Albert Liu
Journal:  Curr Treat Options Infect Dis       Date:  2015-06

4.  Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.

Authors:  Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden
Journal:  Lancet Infect Dis       Date:  2014-07-22       Impact factor: 25.071

5.  Acceptability of drug detection monitoring among participants in an open-label pre-exposure prophylaxis study.

Authors:  Kimberly A Koester; Albert Liu; Christopher Eden; K Rivet Amico; Vanessa McMahan; Pedro Goicochea; Sybil Hosek; Kenneth H Mayer; Robert M Grant
Journal:  AIDS Care       Date:  2015-05-22

6.  Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial.

Authors:  Ariane van der Straten; Ashley Mayo; Elizabeth R Brown; K Rivet Amico; Helen Cheng; Nicole Laborde; Jeanne Marrazzo; Kristine Torjesen
Journal:  AIDS Behav       Date:  2015-05

7.  Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial.

Authors:  Leila Essop Mansoor; Quarraisha Abdool Karim; Lise Werner; Bernadette Madlala; Nelisiwe Ngcobo; Deborah H Cornman; K Rivet Amico; Jeffrey Fisher; William A Fisher; Kathleen M Macqueen; Salim S Abdool Karim
Journal:  AIDS Behav       Date:  2014-05

Review 8.  Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges.

Authors:  James M McMahon; Julie E Myers; Ann E Kurth; Stephanie E Cohen; Sharon B Mannheimer; Janie Simmons; Enrique R Pouget; Nicole Trabold; Jessica E Haberer
Journal:  AIDS Patient Care STDS       Date:  2014-07-21       Impact factor: 5.078

9.  Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco.

Authors:  Hailey J Gilmore; Albert Liu; Kimberly Ann Koester; K Rivet Amico; Vanessa McMahan; Pedro Goicochea; Lorena Vargas; David Lubensky; Susan Buchbinder; Robert Grant
Journal:  AIDS Patient Care STDS       Date:  2013-10       Impact factor: 5.078

10.  HIV providers' perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study.

Authors:  Douglas Krakower; Norma Ware; Jennifer A Mitty; Kevin Maloney; Kenneth H Mayer
Journal:  AIDS Behav       Date:  2014-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.